Document is current
Any future updates will be listed below
-
Authors
Zeyn, Yanira https://orcid.org/0000-0002-2501-8149
Hausmann, Kristin https://orcid.org/0000-0003-3419-5769
Halilovic, Melisa
Beyer, Mandy
Ibrahim, Hany S. https://orcid.org/0000-0002-1048-4059
Brenner, Walburgis
Mahboobi, Siavosh
Bros, Matthias
Sippl, Wolfgang
Krämer, Oliver H. https://orcid.org/0000-0003-3973-045X
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (KR2291, 469954457; SI868/22-1)
Deutscher Akademischer Austauschdienst (N/A)
Alexander von Humboldt-Stiftung (EGY 1191187)
- License Information
-
More Information
Article History
Received: 28 March 2023
Revised: 31 August 2023
Accepted: 12 September 2023
First Online: 21 September 2023
Competing interests
: MBe, SM, and OHK declare the patent “Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors, WO2019/034538”; SM and OHK declare “Novel HDAC6 inhibitors and their uses, WO2016020369A1”; OHK declares “The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity, WO/2004/027418”.
